REGN - Ocular Therapeutix spikes as BofA starts at Buy on Wet AMD prospects
2024-02-09 10:02:33 ET
More on Ocular Therapeutix
- Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD
- Ocular wins FDA nod to change Phase 3 wet AMD trial design
- Biggest stock movers today: Moderna, Foot Locker, Adobe, Ocular Therapeutix and more
- Seeking Alpha’s Quant Rating on Ocular Therapeutix
- Historical earnings data for Ocular Therapeutix